Travere Therapeutics, Inc.·4

Jul 2, 5:28 PM ET

Inrig Jula 4

4 · Travere Therapeutics, Inc. · Filed Jul 2, 2025

Insider Transaction Report

Form 4
Period: 2025-07-01
Inrig Jula
CHIEF MEDICAL OFFICER
Transactions
  • Sale

    Common Stock

    2025-07-01$14.65/sh815$11,94088,787 total
Footnotes (1)
  • [F1]This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of additional shares to cover the tax obligation that occurred upon the vesting of performance-based restricted stock units (PSUs) that vested in February 2025.

Documents

1 file
  • 4
    form4-07022025_090753.xmlPrimary